Dasatinib

Catalog No.S1021 Synonyms: BMS-354825

Dasatinib Chemical Structure

Molecular Weight(MW): 488.01

Dasatinib is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM in cell-free assays, respectively.

Size Price Stock Quantity  
In DMSO USD 140 In stock
USD 147 In stock
USD 370 In stock

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 62 Publications

10 Customer Reviews

  • Combinational treatment of kinase inhibitors induces the similar phenotype produced by PP1. All images are lateral view with dorsal to the top and anterior to the left. The combinational treatment of Dasatinib (D) or U0126 (U) with Sunitinib (SU),PTK787 (PTK), or ZM323881 (Z) resulted in the shrinkage of dorsal aorta.

    Cell Res 2011 21, 1080-1087. Dasatinib purchased from Selleck.

    Cytotoxicity by Dasatinib and Nutlin-3 used alone or in combination in B-CLL patient leukemic cells. B-CLL patient leukemic cells were exposed to serial doses of Dasatinib or Nutlin- 3 used either alone or in combination, with a fixed ratio, for 48 hours. Dose-effect plots, to determine drug efficacy, are shown for representative B-CLL samples, including 3 patients carrying 17p- (Pt. #7, Pt. #8, and Pt. #10). The decrease of cell viability, labeled "effect" on the Y-axis, was determined in assays done at least twice in duplicate.

    Clin Cancer Res 2011 17, 762-770. Dasatinib purchased from Selleck.

  • Dasatinib interferes with the p53 transcriptional activity induced by Nutlin-3. Leukemic cell lines were exposed for 24 hours to Dasatinib (10 μM) and Nutlin-3 (10 μM), used either alone or in combination, as indicated. Levels of p53 (A), MDM2 and p21 (B) were assessed by Western blot analysis of total cell lysates. Representative examples of Western blot results are shown. Tubulin staining is shown as loading control; after densitometric analyses, p53 as well as MDM2 and p21 protein levels are expressed as folds of protein modulation, by the indicated treatments, with respect to the control untreated cultures set to 1 (hatched line). *P < 0.05 with respect to the Nutlin-3-treated cultures.

     

     

    Clin Cancer Res 2011 17, 762-770. Dasatinib purchased from Selleck.

    Role of Akt in Dasatinib cytotoxicity and in DasatinibtNutlin-3 synergy. A, whole cell lysates were prepared from EHEB and BJAB cell lines treated (for 16 hours) as indicated, and hybridized with a human Phospho-Kinase array kit. Spot densities of phospho-proteins were quantified using Image Quant TL software and normalized to those of positive controls (set at 100) on the same membrane. The analysis of modulation of phosphorylation signals for P-ERK1/2, P-p38, and P-Akt are reported (*P < 0.05). Validation of phospho-kinase array results was carried out by Western blot analysis of P-Akt levels.

     

     

    Clin Cancer Res 2011 17, 762-770. Dasatinib purchased from Selleck.

  • Impact of the TKI erlotinib, lapatinib, dasatinib, and sorafenib on the viability of MDS/AML cells. MOLM-13 (A) and HL-60 (B) cells were incubated with the indicated doses (given in mM below the x-axis) of the 4 TKI, and cellular viability was assessed by MTT assay after 24, 48 and 72 h of incubation. Changes in viability are given as percentage of cells as compared to non-treated control samples. This experiment was repeated at least three times, yielding comparable results. Graphs show representative results of one experiment carried out in duplicates (mean standard deviation).

     

     

    Biochem Pharmacol 2011 82, 1457-1466. Dasatinib purchased from Selleck.

    Capacity of the TKI to overcome the AML-typical differentiation blockage. The myeloid cell lines MOLM-13 and HL-60 were incubated for 6 days with 0.01% DMSO (serving as a negative solvent control), 1 μM of ATRA (serving as a positive control), as well as with the indicated doses of the four TKI. (A) Representative May -Gruenwald -Giemsa staining of MOLM-13 cells, (B) quantitation of the percentage of MOLM-13 cells exhibiting at least two morphological signs of differentiation (that is a decrease in cytoplasmic basophilia, a reduction of the nucleo-cytoplasmic ratio, appearance of nuclear lobulation and/or cytoplasmic granules). Percentages were evaluated by examining at least 100 cells/condition; (C) representative FACS overlays of MOLM-13 cells depicting TKI-induced CD11b expression (black line) as compared to the isotype (shaded grey); (D) quantitation of TKI-induced CD11b-expression in MOLM-13 cells; (E) representative slides depicting morphology/staining of MOLM-13 cells assessed in the NBT-reduction assay; (F) respective quantitative assessment demonstrating the NBT-reducing capacity under the different drugs; (G) representative May-Gruenwald-Giemsa staining of HL-60 cells.

     

     

    Biochem Pharmacol 2011 82, 1457-1466. Dasatinib purchased from Selleck.

  • Cytotoxicity by Dasatinib treatment in leukemic cells.Leukemic cell lines were exposed to Dasatinib (10 μM). Upon treatment, cell viability (a) was calculated as percentage with respect to the control vehicle cultures (set to 100% for each cell line) and induction of apoptosis (b) was calculated as percentage of Annexin V+/PI+ cells after 48 h of treatment.

     

     

    Invest New Drugs 2010 30, 417-422. Dasatinib purchased from Selleck.

    Human phospho-kinase array analysis in response to Dasatinib treatment. Whole cell lysates were prepared from EHEB (p53wt) and BJAB (p53mut) B cell lines, either left untreated or exposed to Dasatinib for 24 h, and hybridized with a human Phospho-Kinase array kit. Spot densities of phospho-proteins were quantified using Image Quant TL software and normalized to those of positive controls on the same membrane. In a, intense decreases of signal of P-p38, PERK1/2 and P-CREB in response to Dasatinib are indicated by arrows in the membranes, and intensity of corresponding spots are reported as graphics. In b, analysis of modulation of phosphorylation of STAT family members in response to Dasatinib (spots not shown). The means±SD of three independent experiments are shown. Asterisk indicates P<0.05 against untreated.

    Invest New Drugs 2010 30, 417-422. Dasatinib purchased from Selleck.

  • Cells were either left untreated (Unt.) or exposed to Dasatinib (Das.) for 24 h. Equal amounts of cell lysates were analyzed for ERK1/2, p38 and CREB phosphorylation by Western blot using antibodies specific for the native form of the kinases and for residues that are phosphorylated (P-) in each kinase upon activation. One of three experimentswith similar results is shown. Protein bands were quantified by densitometry and level of PERK1/2, P-p38 and P-CREB expressed as arbitrary units,were calculated for each cell line after normalization to total ERK1/2, p38 and CREB respectively

     

     

    Invest New Drugs 2010 30, 417-422. Dasatinib purchased from Selleck.

    Cell vability test result. Different cell lines (A2C12, Beta D5, Gamma A3, Gamma D12, A549, CaCo2,Hep G2) were treated with different concentration of Dasatinib.

     

     

    Dr. Thomas Kruwel of Fraunhofer-Institute for Toxicology and Experimental Medicine-Dasatinib (BMS-354825) purchased from Selleck. Dasatinib purchased from Selleck.

Purity & Quality Control

Choose Selective Src Inhibitors

Click to view more

Notes:

2. For more details, such as half maximal inhibitory concentrations (IC50s) and working concentrations of each inhibitor, please click on the link of the inhibitor of interest.
3. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation.
4. Orange "√" refers to compounds which do inhibitory effects on the related isoform, but without specific value.

Biological Activity

Description Dasatinib is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM in cell-free assays, respectively.
Targets
Abl [1]
(Cell-free assay)
Src [1]
(Cell-free assay)
c-Kit (D816V) [2]
(Cell-free assay)
c-Kit (wt) [2]
(Cell-free assay)
0.6 nM 0.8 nM 37 nM 79 nM
In vitro

Dasatinib is more effective than imatinib in inhibiting the proliferation of Ba/F3 cells expressing wild-type Bcr-Abl and Bcr-Abl mutants, with the exception of T315I. Dasatinib has a two-log (∼325-fold) increased potency relative to imatinib. Dasatinib potently inhibits wild-type Abl kinase and all mutants except T315I over a narrow range. Dasatinib directly targets wild-type and mutant Abl kinase domains and inhibits autophosphorylation and substrate phosphorylation in a concentration-dependent manner. Dasatinib displays 325-fold greater potency compared with imatinib against cells expressing wild-type Bcr-Abl. [1] The percent of colonies of TgE bone marrow cells are decreased from 100% in untreated wells to 4.12% in Dasatinib treated wells. In the presence of Dasatinib, the difference in the percentage of colonies formed by WT and TgE bone marrow cells is statistically significant. Expression of LMP2A is able to promote B lymphocyte survival and proliferation, which can be inhibited by targeting Lyn and/or c-Abl kinases through Dasatinib. [3] Dasatinib treatment inhibits Src signaling, decreases growth, and induces cell cycle arrest and apoptosis in a subset of thyroid cancer cells. Treatment with increasing doses of Dasatinib (0.019 μM to 1.25 μM) for 3 days inhibits the growth of the C643, TPC1, BCPAP, and SW1736 cell lines by about 50% at low nanomolar concentrations, while higher concentrations are required to inhibit the growth of the K1 cell line. Treatment with 10 nM or 50 nM Dasatinib results in a 9-22% increase of cells in the G1 population among BCPAP and SW1736 and K1 cells, and a corresponding 7-18% decrease in the percentage of cells in the S phase. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
M07ep210 MlPVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3X3fVczKGh? M17rd2ROW09? NEHHc3VKSzVyPUCuNFAxODdizszN M1m0VVE4QTV4MEiw
K562 Mn7RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWq3NkBp M3mzPGROW09? MXXJR|UxRTBwMECxJO69VQ>? MX2xO|k2PjB6MB?=
M07e Mn71S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXy4fGt{PzJiaB?= MUjEUXNQ NF3FdmNKSzVyPUCuNFAyOiEQvF2= NXLMcVFyOTd7NU[wPFA>
ALL3 M37DbGN6fG:2b4jpZ{BCe3OjeR?= NVvYU2JWOC5zzszN MVy3NkBp M4nUVWROW09? NHfIfnFKSzVyPUCuNFAxPCEQvF2= NYXmN4NEOTl6OEm1OFA>
CML NVzWTHU5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3XRZ|IxKG2rbh?= M2PxeGROW09? MljQTWM2OD1yLkCwNUDPxE1? MX:xPVIyQTBzNh?=
BA/F3 Mme5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4TtSVczKGh? MVvEUXNQ M{\DfWlEPTB;Nj61PFkh|ryP MYmyN|A5QDZ2NB?=
BA/F3 M1vwe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{HzPVczKGh? M1[zdmROW09? NXfL[W1oUW6mdXPld{BidnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIV5eHKnc4PpcochSmO{LVHicEBOOzVzVDDteZRidnRid3n0bEBKSzVyIH;mJFAvODByOEROwG0> NE\1b2wzOzB6OE[0OC=>
BA/F3 NFnKbXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHixeIQ4OiCq M330NmROW09? NGXiTnhKdmS3Y3XzJIFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgcY92e2ViQlGvSlMh[2WubIOg[ZhxemW|c3nu[{B4cWymIIT5dIUhSmO{LVHicEB4cXSqIFnDOVAhd2ZiMD6wNFQ2|ryP MmPzNlMxQDh4NES=
BA/F3 MoHNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Moi1O|IhcA>? M{i2VGROW09? NXy4S4FPUW6mdXPld{BidnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIV5eHKnc4PpcochSmO{LVHicEBVOzF3STDteZRidnRid3n0bEBKSzVyIH;mJFEvPzF2zszN MofrNlMxQDh4NES=
BA/F3 MoPpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYnzOpNvPzJiaB?= NWj2WlBYTE2VTx?= NWPXSIdRUW6mdXPld{BkgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBDSS:IMzDj[YxteyCneIDy[ZN{cW6pIFLDVk1CSkxiRkS4OnMhdXW2YX70JIF{e2W|c3XkJIF{KGe{b4f0bEBKdmirYnn0bY9vKHerdHigTWM2OCCxZjCwMlAxODoQvF2= NWjQUoRoOjN|MEG3NFM>
BA/F3 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFX5SIk4OiCq NWX2[ndlTE2VTx?= NH\SNWdKdmS3Y3XzJIN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJCN0Z|IHPlcIx{KGW6cILld5NqdmdiQlPSMWFDVCCHMkW1T{BufXSjboSgZZN{\XO|ZXSgZZMh\3Kxd4ToJGlvcGmkaYTpc44hf2m2aDDJR|UxKG:oIECuNFA{Os7:TR?= NV3meYx3OjN|MEG3NFM>
BA/F3 NYSzT|dPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3T1cVczKGh? MU\EUXNQ M{\TfGlv\HWlZYOgZ5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRmEwTjNiY3XscJMh\XiycnXzd4lv\yCEQ2KtRWJNKEd{NUDFJI12fGGwdDDhd5Nme3OnZDDhd{Boem:5dHigTY5pcWKrdHnvckB4cXSqIFnDOVAhd2ZiMD6wNFUy|ryP Mmi3NlM{ODF5MEO=
BA/F3 NHrrdIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{HVdlczKGh? MorVSG1UVw>? MYTJcoR2[2W|IHP5eI91d3irY3n0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIV5eHKnc4PpcochSkOULVHCUEBSOjV{SDDteZRidnRiYYPz[ZN{\WRiYYOg[5Jwf3SqIFnubIljcXSrb36ge4l1cCCLQ{WwJI9nKDBwMEC4{txO Ml[wNlM{ODF5MEO=
BA/F3 M{KyW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW[3NkBp MnL5SG1UVw>? NHLYXY1KdmS3Y3XzJIN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJCN0Z|IHPlcIx{KGW6cILld5NqdmdiQlPSMWFDVCCHM{W5WkBufXSjboSgZZN{\XO|ZXSgZZMh\3Kxd4ToJGlvcGmkaYTpc44hf2m2aDDJR|UxKG:oIECuNFAyO87:TR?= MVOyN|MxOTdyMx?=
BA/F3 MnvFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYDm[VhyPzJiaB?= M3rk[WROW09? MUfJcoR2[2W|IHP5eI91d3irY3n0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIV5eHKnc4Ppcochf2muZDD0fZBmKEKFUj3BRmwh[XO|ZYPz[YQh[XNiZ4Lve5RpKEmwaHnibZRqd25id3n0bEBKSzVyIH;mJFAvODBzOd88US=> NGS4bY0zOzNyMUewNy=>
BA/F3 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFrNeoU4OiCq M2riUmROW09? MlvkTY5lfWOnczDjfZRwfG:6aXPpeJkh[WejaX7zeEBud3W|ZTDCRU9HOyClZXzsd{BmgHC{ZYPzbY5oKEKFUj3BRmwhYTJ3M1igcZV1[W62IHHzd4V{e2WmIHHzJIdzd3e2aDDJcohq[mm2aX;uJJdqfGhiSVO1NEBw\iByLkCwNlPPxE1? NWHCNGZtOjN|MEG3NFM>
BA/F3 M1r3OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGTKR3c4OiCq NH7BNJJFVVOR NFzKfVZKdmS3Y3XzJIN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJCN0Z|IHPlcIx{KGW6cILld5NqdmdiQlPSMWFDVCCWM{G1TUBufXSjboSgZZN{\XO|ZXSgZZMh\3Kxd4ToJGlvcGmkaYTpc44hf2m2aDDJR|UxKG:oIEOuOu69VQ>? Mm\5NlM{ODF5MEO=
BA/F3 NXPYUodrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUG3NkBp M1LrV2ROW09? MY\JcoR2[2W|IHP5eI91d3irY3n0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIF{e2W|c3XkJIF{KGe{b4f0bEBKdmirYnn0bY9vKHerdHigTWM2OCCxZjCyMlXPxE1? MUmyN|MxOTdyMx?=
T cell MnjNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWjPcmJ7PzJiaB?= Mn\0SG1UVw>? MXTJcohq[mm2czDhcpRqKEOGMz2gZY5lKGGwdHmgR2QzQC2rbnT1Z4VlKFRiY3XscEBxem:uaX\ldoF1cW:wIIfpeIghUUN3MDDv[kAxNjByM988US=> MmTQNVcyPTR3MUK=
WiDr M2q2ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3Hib|czKGh? NEDGT2NFVVOR NYTEcFdHUUN3ME2wMlA2OiEQvF2= M3XDcVE2PjF3NUGy
PC3 NFjKN25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVG3NkBp NF7EbVdFVVOR NULyc3Q5UUN3ME2wMlAxQTRizszN Ml7FNVU3OTV3MUK=
MDA-MB-231 M{DpUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUO3NkBp NFTWcY5FVVOR NYW2OItlUUN3ME2wMlAyOiEQvF2= M{fNPVE2PjF3NUGy
Hs578T M3LpfWN6fG:2b4jpZ{BCe3OjeR?= NXjubop3PzJiaB?= MmHHSG1UVw>? Mm\xS2k2OD1yLkCzJO69VQ>? NGHQcGczPDBzNUOyOy=>
HMEC MV;DfZRwfG:6aXOgRZN{[Xl? MmPjO|IhcA>? MmfJSG1UVw>? NWXTPHRnT0l3ME2xMlgh|ryP NGD0SXQzPDBzNUOyOy=>
DU145 NIfqW4VEgXSxdH;4bYMhSXO|YYm= Mk\DO|IhcA>? M1\lZ2ROW09? NFHTNYxIUTVyPUCuNVYh|ryP Mnn6NlQxOTV|Mke=
U251 NUPDbpQ4S3m2b4TvfIlkKEG|c3H5 Ml\3O|IhcA>? NVnEVldRTE2VTx?= M3TZW2dKPTB;Mj64NUDPxE1? Mn\PNlQxOTV|Mke=
NCI60 M1;TXGN6fG:2b4jpZ{BCe3OjeR?= MknxO|IhcA>? M32ySmROW09? MUjHTVUxRTVwNzFOwG0> NYTzRZBUOjRyMUWzNlc>
MALME-3M NHLnUHREgXSxdH;4bYMhSXO|YYm= NV\C[2g1PzJiaB?= NVzDXWRjTE2VTx?= NHT0[lVIUTVyPU[uOlEh|ryP MlnsNlQxOTV|Mke=
KM12 M1fvfmN6fG:2b4jpZ{BCe3OjeR?= MnexO|IhcA>? MYnEUXNQ MWHHTVUxRTdwNESg{txO M4D1RVI1ODF3M{K3
SW620 NF[xdGVEgXSxdH;4bYMhSXO|YYm= MnL4O|IhcA>? NXPIbZAyTE2VTx?= MlHSS2k2OD16LkSzJO69VQ>? Mor0NlQxOTV|Mke=
RXF 393NL NWLPZ5JsS3m2b4TvfIlkKEG|c3H5 MlLEOEBl[Xm| NHvTfG1FVVOR NGr6XlBKSzVyPUCuNFIyPyEQvF2= MUWyN|I2OzB5NB?=
LXFA 983L NFS0bZZEgXSxdH;4bYMhSXO|YYm= NGjzPW41KGSjeYO= M2[wcWROW09? MWjJR|UxRTBwMEW2OUDPxE1? M2nlT|I{OjV|MEe0
PRXF DU145 MUTDfZRwfG:6aXOgRZN{[Xl? MVy0JIRigXN? NW\qbo1ETE2VTx?= NGrDd|RKSzVyPUCuNFYzOyEQvF2= NHv2UpYzOzJ3M{C3OC=>
PAXF 1657L MlfTR5l1d3SxeHnjJGF{e2G7 NU\2[pdVPCCmYYnz NFPNOVBFVVOR NVLDRoZ2UUN3ME2wMlEzOSEQvF2= M3e3XVI{OjV|MEe0
CXF 1103L NUP1eYZKS3m2b4TvfIlkKEG|c3H5 M1fqWFQh\GG7cx?= NHq5RVZFVVOR MnuxTWM2OD12LkO2JO69VQ>? NIrSTIQzOzJ3M{C3OC=>
GXF251L NYHu[WhQS3m2b4TvfIlkKEG|c3H5 NH3Ebmo1KGSjeYO= NGXmW5lFVVOR MVfJR|UxRTJwMkWg{txO MWKyN|I2OzB5NB?=
NCI-H23 M4r2UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmTlO|IhcA>? NFf4W3dFVVOR MUDJR|UxRTJwMkeg{txO MmDSNlM2OjFyMkC=
HCT116 NVjQS4twT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEjuNmI4OiCq M3zCcGROW09? MlrqTWM2OD1{LkOg{txO NFHRZZQzOzV{MUCyNC=>
MCF7 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX63NkBp NWLweJhuTE2VTx?= NX62PIIxUUN3ME2yMlU4KM7:TR?= MlTQNlM2OjFyMkC=
NCI-H460 NUnC[phPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3vVOVczKGh? MlHLSG1UVw>? MWrJR|UxRThwOUmg{txO Mn7VNlM2OjFyMkC=
DLD1 M4q2dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm[3O|IhcA>? MUnEUXNQ NGj0cXdKSzVyPUSuOkDPxE1? M3zOeVI{PTZ5OU[w
NCI-H661 NWCwSVdPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXTUfJBGPzJiaB?= NH\4VGdFVVOR NFL6OIZKSzVyPUeuPEDPxE1? NFriXXIzOzV4N{m2NC=>
A549 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV:3NkBp MmGzSG1UVw>? MWPJR|UxRThwMjFOwG0> MU[yN|U3Pzl4MB?=
U937 M1L2Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWexVpNOPzJiaB?= MXPEUXNQ NFy3d4pKSzVyPUGyMlIh|ryP NIfVfWszOzV4N{m2NC=>
HEK293 NG\obWtHfW6ldHnvckBCe3OjeR?= M4[0NlExyqEQvF2= NFj2XIFFVVOR M{C2RWlv\HWlZYOgZolv\GmwZzDh[oZqdmm2eTD0c{BpfW2jbjDmeYxtNWynbnf0bEBJcXNvdHHn[4VlKE27dEGgb4lv[XOnIHX4dJJme3OnZDDpckBJTUt{OUOgZ4VtdHNid3n0bEBKSzVyIH;mJFAvODZ|zszN M1fCN|IzPzdyNkGw
HUVEC M3PhR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkjzNE4yPcLizszN MYq3NkBp NH25OZZFVVOR NVn5Zo5yUW6mdXPld{BidnSrYX7nbY9o\W6rYzDhZ5Rqfmm2eTDpckBJXV[HQzDjc{1kfWy2dYLl[EB4cXSqII\hd4N2dGG{IIPtc491cCCvdYPjcIUh[2WubIOgZZN{\XO|ZXSgZZMhUW6qaXLpeIlwdiCxZjDj[YxtKGe{b4f0bEBifCByLkG1JJVO MUGyNlg2Ozl7Mx?=
HUVEC NHHTXJNHfW6ldHnvckBCe3OjeR?= M{C5OVE2yqEQvF2= NHzScJU4OiCq Mo\WSG1UVw>? NFfiWYVKdmS3Y3XzJIFvfGmjbnfpc4dmdmmlIHHjeIl3cXS7IHnuJGhWXkWFIHPvMYN2dHS3cnXkJJdqfGhidnHzZ5Vt[XJic33vc5RpKG23c3Ps[UBk\WyuczDhd5Nme3OnZDDhd{BKdmirYnn0bY9vKG:oIH7leJdwemtiZn;ycYF1cW:wIHH0JFEvQCC2bzCxOUB2VQ>? M3SyUlIzQDV|OUmz
Plasmodium falciparum MUHGeY5kfGmxbjDBd5NigQ>? NVzZOolROTEEoN88US=> NGPRTmoyPSCvaX6= NITDUFRFVVOR M17xSGlvcGmkaYTzJHBt[XOvb3TpeY0h\mGuY3nwZZJ2dSCycn;sbYZmemG2aX;uJIJ6KGmwaHnibZRqdmdidHjlJGZ2dmO2aX;uJI9nKFCoQ1TQT|EheHKxdHXpckB4cXSqIFnDOVAhd2ZiMT6xO:69VQ>? NWHTeoZNOjR3NUCzN|A>
PC3 Ml7ISpVv[3Srb36gRZN{[Xl? M{LCRlAvOSEQvF2= MkPnOUBp M3\IPGROW09? M3\UPWlvcGmkaYTzJIh2dWGwIGDDN{Bk\WyuIHHkbIV{cW:wIHH0JFExOCCwTR?= NVXvV|F3OTl2NkK5O|U>
DU145 MmWzSpVv[3Srb36gRZN{[Xl? NVnnd4dZOC5zIN88US=> NYjRZXhVPSCq NUWyN2ZnTE2VTx?= NIDjN5hKdmirYnn0d{BpfW2jbjDEWVE1PSClZXzsJIFlcGW|aX;uJIF1KDFyMDDuUS=> NFLTNIIyQTR4Mkm3OS=>
PC3 MV7LbY5ie2ViQYPzZZk> NHjDbIQxNjFizszN MUK1JIg> MWnEUXNQ NGj4fJJKdmirYnn0d{BkW3KlIHnuJIh2dWGwIGDDN{Bk\WyuczDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hd2ZicHjvd5Bpd3K7bHH0[YQhW3KlIGm0NVYhdGW4ZXygZZQhOTByIH7N NULm[4RSOTl2NkK5O|U>
DU145 NHXZZ3JMcW6jc3WgRZN{[Xl? M4GydVAvOSEQvF2= M{\aOlUhcA>? M{myVmROW09? NI\UWYNKdmirYnn0d{BkW3KlIHnuJIh2dWGwIFTVNVQ2KGOnbHzzJIF{e2W|c3XkJIF{KHKnZIXjeIlwdiCxZjDwbI9{eGixconsZZRm\CCVcnOgXVQyPiCuZY\lcEBifCBzMECgcm0> MX[xPVQ3Ojl5NR?=
PC3 NVL2SoxFU2mwYYPlJGF{e2G7 M3\kblAvOSEQvF2= M2Tr[lUhcA>? NUfZU5NFTE2VTx?= NXW0[257UW6qaXLpeJMh[1O{YzDpckBpfW2jbjDQR|Mh[2WubIOgZZN{\XO|ZXSgZZMhemWmdXP0bY9vKG:oIIDoc5NxcG:{eXzheIVlKE[DSzDZOVc3N1l3N{egcIV3\WxiYYSgNVAxKG6P M{OwPFE6PDZ{OUe1
DU145 NVjqN2RWU2mwYYPlJGF{e2G7 MV2wMlEh|ryP MlzqOUBp M2T1e2ROW09? MlqzTY5pcWKrdIOgZ3Nz[yCrbjDoeY1idiCGVUG0OUBk\WyuczDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hd2ZicHjvd5Bpd3K7bHH0[YQhTkGNIGm1O|YwYTV5NzDs[ZZmdCCjdDCxNFAhdk1? MnPwNVk1PjJ7N{W=
Huh7 NVLwZZFFSW62aY\pdoFtKEG|c3H5 M1HFXlIvPSEQvF2= M4Ts[VQh\GG7cx?= NFP2RXpFVVOR NVjHblZ5UW6qaXLpeJMhfmm{YXygd5Bz\WGmIHnuJGRmdme3ZTD2bZJ2ey2rbn\lZ5Rm\CCqdX3hckBJfWh5IHPlcIx{KGG|c3Xzd4VlKGG|IHHjZ5VufWyjdHnvckBw\iC4aYLhcEBmdn[nbH;w[UBxem:2ZXnuJJdqfGirbjDw[ZJqdnWlbHXhdkBz\Werb36gZZQhOi53IIXN M13CSFE4OzZyNke2
C6/36 NWHsVmRzSW62aY\pdoFtKEG|c3H5 MlrrNk42KM7:TR?= M2m5blQh\GG7cx?= NVfXbXoxTE2VTx?= MnzQTY5pcWKrdIOgeolz[Wxic4Dy[YFlKGmwIFTlcod2\SC4aYL1d{1qdm[nY4Tl[EBie2mjbjD0bYdmeiCvb4PxeYl1dyCFNj:zOkBk\WyuczDhd5Nme3OnZDDhd{Bi[2O3bYXsZZRqd25ib3[geolz[WxiZX72[YxweGVicILveIVqdiC5aYTobY4heGW{aX71Z4xm[XJicnXnbY9vKGG2IEKuOUB2VQ>? MXOxO|M3ODZ5Nh?=
U937 MVjGeY5kfGmxbjDBd5NigQ>? NVz0VId6OSEQvF2= NIi3fJQyKGh? NYjDbHdXTE2VTx?= NV\WbYZkWmWmdXPld{Bj[XOjbDDUUmZidHCqYTDy[Yxm[XOnIHnuJIh2dWGwIGW5N|ch[2WubIO= MnHSNVc3QDRyOUm=
U937 M2jEOWZ2dmO2aX;uJGF{e2G7 M3vwU|Eh|ryP M33pU|EhcA>? NVrEbm5MTE2VTx?= MUTS[YR2[2W|IFzQV{1qdmS3Y3XkJHRPTmGucHjhJJJmdGWjc3WgbY4hcHWvYX6gWVk{PyClZXzsdy=> NHPOSXkyPzZ6NEC5PS=>
murine mast cell MlLhSpVv[3Srb36gRZN{[Xl? M2KxOlEh|ryP NGjUOWwzPCCq M2PhemROW09? M2e2SGlvcGmkaYTzJIFvfGmpZX6tbY5lfWOnZDDJUFYhe2WlcnX0bY9vKGmwIFnnSUBxemmvZXSgcY92e2VibXHzeEBk\WyuczDheEAyKHWP NVjtVFkzOTd4OESwPVk>
BV-173 NXzMSnhIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M17wb2lEPTB;MD6wNFAxODBzMEmg{txO NXP4[2FuW0GQR1XS
K-562 NXS2NYJUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmPyTWM2OD1yLkCwNFAxODJ4NjFOwG0> MVXTRW5ITVJ?
BL-70 NVKyO2tyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH3Oe2VKSzVyPUCuNFAxODByOEKyJO69VQ>? NWrPV495W0GQR1XS
EM-2 NEm0[2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3\FbmlEPTB;MD6wNFAxODFyODFOwG0> NH72cI5USU6JRWK=
LAMA-84 NGflUlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYraSYhnUUN3ME2wMlAxODByM{KxJO69VQ>? MnPoV2FPT0WU
MEG-01 NXj1[pVIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlnVTWM2OD1yLkCwNFAxQThizszN MWrTRW5ITVJ?
EoL-1-cell NFjvNotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX\JR|UxRTBwMECwNFE{OSEQvF2= NFK3NpVUSU6JRWK=
CTV-1 NX3KbnN[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlXOTWM2OD1yLkCwNFA1ODRizszN M{n5eHNCVkeHUh?=
TE-15 MnrpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHWyVFNKSzVyPUCuNFA2QDlizszN NUnrPIRGW0GQR1XS
NOS-1 MlPTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4fkcGlEPTB;MD6wNFYyOyEQvF2= M4D0fHNCVkeHUh?=
D-336MG NULVNpczT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3rheGlEPTB;MD6wNFY{KM7:TR?= NITkNplUSU6JRWK=
LB1047-RCC NVvCW5lJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVHkOVdjUUN3ME2wMlAxQTh7IN88US=> MoflV2FPT0WU
LB996-RCC NXPuXJEzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3:0UWlEPTB;MD6wNFk6OSEQvF2= MmryV2FPT0WU
SW982 NVfVfFFXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{iyXWlEPTB;MD6wNVEyPSEQvF2= M3TVS3NCVkeHUh?=
TK10 NIXV[HJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX7JR|UxRTBwMEGxO|Qh|ryP MmHPV2FPT0WU
A704 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIP1O2RKSzVyPUCuNFE1QTFizszN NEf0cVJUSU6JRWK=
TE-8 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFz0dVNKSzVyPUCuNFE2PzZizszN M1;5S3NCVkeHUh?=
DOHH-2 NX:zVGhqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmHuTWM2OD1yLkCxO|E6KM7:TR?= MkDqV2FPT0WU
HOP-62 M3\JTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGTDOWNKSzVyPUCuNFE5OzRizszN MVjTRW5ITVJ?
TE-12 M1LoXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYDLSlJbUUN3ME2wMlAyQDZzIN88US=> MWHTRW5ITVJ?
KGN MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUfJR|UxRTBwMEG5OFIh|ryP MmG3V2FPT0WU
NCI-H1648 M1XmeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkHpTWM2OD1yLkCyNFEyKM7:TR?= MkHMV2FPT0WU
OS-RC-2 NFH0SY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2nnSGlEPTB;MD6wNlA{KM7:TR?= MYHTRW5ITVJ?
GB-1 NIDMTWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1\jb2lEPTB;MD6wNlE2PyEQvF2= NXe2fIZmW0GQR1XS
RXF393 NFjGR3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mk[0TWM2OD1yLkCyN|U4KM7:TR?= MUHTRW5ITVJ?
LC-2-ad M2jDdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoHHTWM2OD1yLkCyOVg3KM7:TR?= M4rJfnNCVkeHUh?=
KS-1 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWPoR5RHUUN3ME2wMlAzPzNizszN M3zJ[HNCVkeHUh?=
ETK-1 M3;PT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkG1TWM2OD1yLkCyPFMzKM7:TR?= Mo\VV2FPT0WU
SW954 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoHSTWM2OD1yLkCyPVI4KM7:TR?= NELCTXFUSU6JRWK=
Becker M2CwZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY\JR|UxRTBwMEOwNFMh|ryP Mn;KV2FPT0WU
MZ1-PC MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVjJR|UxRTBwMEOxNVkh|ryP NX3sUZBGW0GQR1XS
ES6 NXTicIQ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmizTWM2OD1yLkCzNVk{KM7:TR?= NG\WZ5hUSU6JRWK=
KURAMOCHI MlTPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4qxbWlEPTB;MD6wN|Q5PyEQvF2= NWLDdGdpW0GQR1XS
CGTH-W-1 M1vhXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHjafnJKSzVyPUCuNFM2PDhizszN NYDFbWJEW0GQR1XS
VA-ES-BJ MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIrQPVJKSzVyPUCuNFM6ODJizszN M3zHOnNCVkeHUh?=
LXF-289 M{nKNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUTJR|UxRTBwMEO5OVYh|ryP MXrTRW5ITVJ?
MPP-89 NWjXe4hVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{frfmlEPTB;MD6wOFA1QSEQvF2= NFW4TG5USU6JRWK=
SW872 M1\USWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUjJR|UxRTBwMESxOlEh|ryP MofGV2FPT0WU
SNB75 MmrSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MY\JR|UxRTBwMES0N|Uh|ryP NInhZVVUSU6JRWK=
PSN1 M{Lsemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVTlT5Z5UUN3ME2wMlA1PDd2IN88US=> MX;TRW5ITVJ?
LB831-BLC MmrjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2LkSWlEPTB;MD6wOFYxQSEQvF2= MofXV2FPT0WU
MFH-ino NYHT[JkzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlrzTWM2OD1yLkC0O|I1KM7:TR?= M13JR3NCVkeHUh?=
TGBC24TKB MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUT6XJV4UUN3ME2wMlA1PzZzIN88US=> M{LFVnNCVkeHUh?=
A388 NFX0NmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFLzfnRKSzVyPUCuNFUxQTVizszN NUXZdIpFW0GQR1XS
BB30-HNC NHridWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M37UWGlEPTB;MD6wOVQ{PyEQvF2= MmC2V2FPT0WU
GI-ME-N NF2wflZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M12yRmlEPTB;MD6wOlEyQCEQvF2= NIrXVWRUSU6JRWK=
TGBC1TKB NIrnS2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MknaTWM2OD1yLkC2NVY1KM7:TR?= MoDaV2FPT0WU
TE-10 NYDQTZJQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3K2RmlEPTB;MD6wOlM2PyEQvF2= M2L5XHNCVkeHUh?=
A498 NUHOVVFiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mor6TWM2OD1yLkC3Nlg1KM7:TR?= MnzkV2FPT0WU
TE-11 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYDJR|UxRTBwMEe4OVgh|ryP NE\VUlhUSU6JRWK=
BB65-RCC M4CwcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUTJR|UxRTBwMEiyNlch|ryP MYTTRW5ITVJ?
C2BBe1 NWXyNpZsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo\UTWM2OD1yLkC4N|A5KM7:TR?= NUXs[HlmW0GQR1XS
NCI-H747 NEDvN4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVvuVVYyUUN3ME2wMlA5OzZ{IN88US=> MY\TRW5ITVJ?
IST-MES1 MmXlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXjJR|UxRTBwMEi1OVIh|ryP MmrnV2FPT0WU
KALS-1 MnnRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M33nUmlEPTB;MD6wPVQ6KM7:TR?= NH\pUYNUSU6JRWK=
GCIY MkXxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmLUTWM2OD1yLkC5OlU3KM7:TR?= NYO0O2JMW0GQR1XS
RL95-2 NFrlWGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVHibItjUUN3ME2wMlExOzhizszN M4HxbHNCVkeHUh?=
TE-1 NHXjdndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVLJR|UxRTBwMUC1OEDPxE1? MWrTRW5ITVJ?
NCI-H1355 MmjoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIfFSpFKSzVyPUCuNVExOjhizszN NWfMXlM5W0GQR1XS
SW962 NUDOdFQzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYDJR|UxRTBwMUGyPVIh|ryP NGnaVXFUSU6JRWK=
KLE MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3TmSWlEPTB;MD6xNVMyPyEQvF2= Mnr0V2FPT0WU
MC116 MljkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXnJR|UxRTBwMUG0NUDPxE1? MlLKV2FPT0WU
NMC-G1 NVyxO|hCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIfMVFJKSzVyPUCuNVE3ODZizszN NF\yRpNUSU6JRWK=
KU812 M2H0WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mk\iTWM2OD1yLkGxPFg{KM7:TR?= MVjTRW5ITVJ?
COLO-829 NYrFO3pNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml22TWM2OD1yLkGyNlE{KM7:TR?= MYrTRW5ITVJ?
NTERA-S-cl-D1 MnfaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXP0eodYUUN3ME2wMlEzOjh|IN88US=> MlLDV2FPT0WU
IST-MEL1 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoL1TWM2OD1yLkGzOFUh|ryP M{j3TnNCVkeHUh?=
MLMA Ml7oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV3JR|UxRTBwMUSwN|Ih|ryP MnXyV2FPT0WU
LS-123 M2rNemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWjmbHRVUUN3ME2wMlE1ODZ2IN88US=> MkHHV2FPT0WU
LB2518-MEL MmnuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGjSbohKSzVyPUCuNVQyPjJizszN NIW2NINUSU6JRWK=
NB69 NYfpUHNDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF3ab3JKSzVyPUCuNVQ1OzZizszN NXXyfHluW0GQR1XS
8-MG-BA NHraSnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYHJR|UxRTBwMUW0OVgh|ryP NVLhOmNFW0GQR1XS
K5 NUjtUFA{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoP0TWM2OD1yLkG2OFg6KM7:TR?= NXfNTpJ{W0GQR1XS
KINGS-1 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{joTmlEPTB;MD6xOlY3PiEQvF2= M{TFW3NCVkeHUh?=
SF268 MlLxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn\PTWM2OD1yLkG3OFA1KM7:TR?= MWDTRW5ITVJ?
PF-382 NHSxRoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoPxTWM2OD1yLkG3Olc5KM7:TR?= MUjTRW5ITVJ?
SH-4 NILRdpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUnJR|UxRTBwMUi0NVMh|ryP M1O2OnNCVkeHUh?=
NALM-6 M1LTemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXjO[HVpUUN3ME2wMlE6Ojl3IN88US=> NYLWdWxQW0GQR1XS
CP66-MEL MnTWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIPzeGhKSzVyPUCuNVk2OzFizszN NYrtc25ZW0GQR1XS
697 MofTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVfL[pBMUUN3ME2wMlE6QTh5IN88US=> NIPtbWtUSU6JRWK=
CP67-MEL NI[3T5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVLJR|UxRTBwMkC0PFgh|ryP NGCz[nFUSU6JRWK=
DSH1 M37ofGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoLDTWM2OD1yLkK0NFAyKM7:TR?= NG\Y[YxUSU6JRWK=
HCE-4 M3fSRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkjLTWM2OD1yLkK2OFM6KM7:TR?= M2fHV3NCVkeHUh?=
MZ2-MEL M1u5Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUjJR|UxRTBwMki1N|ch|ryP NVy4TnlkW0GQR1XS
BL-41 NFS5TJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTBwMkmxNlMh|ryP MVvTRW5ITVJ?
HUTU-80 M1rjd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3XzcmlEPTB;MD6zNVQzKM7:TR?= NVzRdVB7W0GQR1XS
LOXIMVI MkO3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXXJR|UxRTBwM{G1NFMh|ryP NEnk[GFUSU6JRWK=
no-10 Mo\0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX7JR|UxRTBwM{G5N|Eh|ryP M2X5OHNCVkeHUh?=
KARPAS-422 NVm0[4FGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUPJR|UxRTBwM{O5PVch|ryP NFLXOo9USU6JRWK=
SW684 MkLYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2LqWGlEPTB;MD6zOFk5KM7:TR?= NWX4UoFFW0GQR1XS
SF126 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUXteoc3UUN3ME2wMlM2PDFizszN MVTTRW5ITVJ?
D-263MG NH3wfWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWnJR|UxRTBwM{[yNlQh|ryP MYDTRW5ITVJ?
OVCAR-4 NGjuXVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW\JR|UxRTBwM{e0N|Mh|ryP M3O4bXNCVkeHUh?=
BB49-HNC M3qzc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmHZTWM2OD1yLkO4OVk6KM7:TR?= NXnteYg5W0GQR1XS
ONS-76 NWTKZ49tT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXTJR|UxRTBwNEK5OVEh|ryP NYfaPHpiW0GQR1XS
MZ7-mel NEDzS2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2rTUGlEPTB;MD60O|kyOSEQvF2= M2i4OHNCVkeHUh?=
RCC10RGB NVjMXnVtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXPHU|VmUUN3ME2wMlQ6OTFizszN NXnJdVJsW0GQR1XS
BOKU NHnNcHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVzpWlU3UUN3ME2wMlQ6OTN|IN88US=> MUnTRW5ITVJ?
no-11 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYTiPXFsUUN3ME2wMlUxOjJ6IN88US=> MVvTRW5ITVJ?
IST-SL2 NEDEW5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3HWfGlEPTB;MD61NFMxOiEQvF2= NI\rcYlUSU6JRWK=
RKO M4LjZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGLvTYNKSzVyPUCuOVI6PjZizszN M4fQNHNCVkeHUh?=
HT-144 M1fCWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYjJR|UxRTBwNUO2NFkh|ryP M3jlfnNCVkeHUh?=
NCI-H446 MlTqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFy0cXNKSzVyPUCuOlI4PiEQvF2= MlLzV2FPT0WU
QIMR-WIL M2HLWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIjYVohKSzVyPUCuO|A3OjlizszN M3v1XnNCVkeHUh?=
MHH-PREB-1 M2\yVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX\5OoFEUUN3ME2wMlc1PDZ7IN88US=> MWDTRW5ITVJ?
EW-16 M{[3Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoPqTWM2OD1yLke2NVc5KM7:TR?= MVvTRW5ITVJ?
EW-24 MnLiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIrxXJhKSzVyPUCuO|gyPjVizszN MXfTRW5ITVJ?
LB373-MEL-D MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXrJR|UxRTBwOEK1NFgh|ryP NVzBOVlQW0GQR1XS
TE-9 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnS2TWM2OD1yLki3OVMzKM7:TR?= MYXTRW5ITVJ?
A3-KAW MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn[wTWM2OD1yLkm4OFUzKM7:TR?= NF;rV2pUSU6JRWK=
A101D M2rHO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkP3TWM2OD1zLkCzNFQ{KM7:TR?= NVmyZ|hzW0GQR1XS
OCUB-M NXzqWIo4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVr5cpZvUUN3ME2xMlA1PDF{IN88US=> MVrTRW5ITVJ?
ES4 MlXQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn7ITWM2OD1zLkC1NVQ2KM7:TR?= M{\ZNXNCVkeHUh?=
TE-6 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MljETWM2OD1zLkKxNlI3KM7:TR?= NHfNb3ZUSU6JRWK=
D-502MG NIi0TJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGrDU2NKSzVyPUGuNlM{PzZizszN M4fJOXNCVkeHUh?=
KNS-42 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnLDTWM2OD1zLkK0OFEzKM7:TR?= M2j6e3NCVkeHUh?=
SNU-C2B M2\DTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3zkOGlEPTB;MT6zNFU5QSEQvF2= NFfPWmdUSU6JRWK=
NCI-H1838 NG\mNlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIi4R5dKSzVyPUGuN|A4OzNizszN NF3tS4pUSU6JRWK=
NKM-1 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4T1[mlEPTB;MT6zNFg2QSEQvF2= M1;6TnNCVkeHUh?=
GI-1 MknwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHzx[2tKSzVyPUGuN|YzOiEQvF2= NX74dY9WW0GQR1XS
NB5 NIe0N4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH7U[4FKSzVyPUGuN|k5OjdizszN NFraNHRUSU6JRWK=
CAS-1 M4H2[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3ToPWlEPTB;MT60NFk6OiEQvF2= MXXTRW5ITVJ?
HCE-T NFnJTINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1z3bGlEPTB;MT61OlcyPCEQvF2= NV;NTnppW0GQR1XS
SBC-1 Mk\HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mm\VTWM2OD1zLkW3PVg1KM7:TR?= NULyeY46W0GQR1XS
JiyoyeP-2003 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2PUeGlEPTB;MT63N|Q3PiEQvF2= MlPuV2FPT0WU
TE-5 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFvQ[nhKSzVyPUGuO|kyOzlizszN NFLGbJZUSU6JRWK=
CAN NEPHfFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnOxTWM2OD1zLkiyNlUzKM7:TR?= M4W0cXNCVkeHUh?=
SK-UT-1 NGn6UXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1LZS2lEPTB;Mj6xOlY6OyEQvF2= MV;TRW5ITVJ?
JVM-2 MknJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4jXfmlEPTB;Mj6zOlI5PCEQvF2= NYO5cHhZW0GQR1XS
LB771-HNC NFi5dnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2fYUGlEPTB;Mj61O|U2OSEQvF2= NU\sTWxnW0GQR1XS
NCCIT MofkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{\TO2lEPTB;Mj64OlYyPiEQvF2= MX3TRW5ITVJ?
NCI-H2126 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2XXPWlEPTB;Mj64O|U2OiEQvF2= MmK5V2FPT0WU
Calu-6 M1\YUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU\JR|UxRTNwMEW3OFEh|ryP NVO3WI9EW0GQR1XS
SK-LMS-1 NWP2TVJLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1SzRmlEPTB;Mz6xNVg5PiEQvF2= NWLWNVZkW0GQR1XS
ARH-77 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkPkTWM2OD1|LkS2PVE2KM7:TR?= MXrTRW5ITVJ?
NB17 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW\JR|UxRTNwNkO4OFch|ryP M2LXWHNCVkeHUh?=
A253 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoXnTWM2OD1|LkezNlQ3KM7:TR?= NGHC[4tUSU6JRWK=
OPM-2 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1zBd2lEPTB;ND6yO|Y5PSEQvF2= NXfUcoZvW0GQR1XS
MV-4-11 Mmq4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWLZRpVEUUN3ME20MlM3PDV2IN88US=> Ml;1V2FPT0WU
SR NEm5[XBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUT3SFJDUUN3ME20MlQ6QTV2IN88US=> MWXTRW5ITVJ?
KG-1 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2DsSWlEPTB;ND62NFg1PSEQvF2= NGHKUItUSU6JRWK=
OCI-AML2 NVva[lF1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH30dVlKSzVyPUWuPFYyPTRizszN NXjoWodGW0GQR1XS
D-247MG M{fjS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NW\Qc5ZrUUN3ME22MlEzPTF7IN88US=> M2TIbXNCVkeHUh?=
DJM-1 Mn\nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmXSTWM2OD14LkS4OVU5KM7:TR?= M3S2e3NCVkeHUh?=
RPMI-6666 MluyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlvWTWM2OD15LkK3NFY4KM7:TR?= NU[3bJFwW0GQR1XS
KARPAS-45 NYf1NGgyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnrKTWM2OD15LkWxOlcyKM7:TR?= Mn24V2FPT0WU
LP-1 M2T3bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXXkbG9ZUUN3ME23MlU1Pzh{IN88US=> NYTwXlc4W0GQR1XS
RS4-11 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVTJR|UxRTdwNkW3PFch|ryP NVrTcmplW0GQR1XS
DU-4475 NEO0SGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M17u[mlEPTB;OD6yNVY2OiEQvF2= M3e2bHNCVkeHUh?=
MONO-MAC-6 MkDES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUDJR|UxRThwMkewOlYh|ryP MVjTRW5ITVJ?
NCI-SNU-16 MortS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX3JR|UxRThwNU[xNlgh|ryP NILUZVRUSU6JRWK=
SJSA-1 NV74NVlxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUnJR|UxRThwN{K4NFUh|ryP NX;aZ5p3W0GQR1XS
MMAC-SF MmHyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXXJR|UxRThwN{mzNFch|ryP MknnV2FPT0WU
SK-NEP-1 MoPCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRThwOEmxOVUh|ryP NFLr[2VUSU6JRWK=
J-RT3-T3-5 MlXnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MY\JR|UxRThwOU[1Nlkh|ryP MlLlV2FPT0WU
SKM-1 M4jHNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVvP[YVNUUN3ME25MlAyPzN2IN88US=> NGm5V|JUSU6JRWK=
LB2241-RCC MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWjJR|UxRTlwMEKwNVIh|ryP MVfTRW5ITVJ?
SIG-M5 NVS3RmNsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVnCZnZLUUN3ME25MlAzPDl|IN88US=> M3\uXHNCVkeHUh?=
EVSA-T MnjUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1z2[WlEPTB;OT6yO|c6OyEQvF2= MnTsV2FPT0WU
GT3TKB NWf4OYdVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWTJR|UxRTlwM{W1OFYh|ryP MoixV2FPT0WU
NB6 NGrtVGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlHqTWM2OD17LkmyNlU6KM7:TR?= NHn1O5dUSU6JRWK=
EHEB M4jkS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV7JR|UxRTFyLkC2OVYh|ryP MYLTRW5ITVJ?
HEL NHvWb2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4LOT2lEPTB;MUCuOFc4PiEQvF2= NIjDW5VUSU6JRWK=
ALL-PO MmKwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH3W[XpKSzVyPUGwMlc6OzhizszN MVjTRW5ITVJ?
TGW M{fpWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnjjTWM2OD1zMT6yPFI5KM7:TR?= NUPYcnlyW0GQR1XS
BC-3 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnTwTWM2OD1zMj6xNVM5KM7:TR?= NGTHSWFUSU6JRWK=
IA-LM M4GzNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmfGTWM2OD1zMj60OFQ2KM7:TR?= MWLTRW5ITVJ?
UACC-257 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYPJR|UxRTF{LkmxPVgh|ryP NVr4Z2xrW0GQR1XS
KP-N-YS M{PaZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoP1TWM2OD1zMj65Nlg{KM7:TR?= MYHTRW5ITVJ?
Raji M3TXemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NID6ZXlKSzVyPUGzMlc1QTdizszN MYDTRW5ITVJ?
SF539 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|UxRTF|Lki1OVch|ryP M2DsOnNCVkeHUh?=
DMS-153 M4XQNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHLiRXBKSzVyPUG0MlAxOjhizszN MoHhV2FPT0WU
L-540 MnniS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHLrVIZKSzVyPUG1MlA3PzJizszN MU\TRW5ITVJ?
MN-60 NXuybnBqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEPuU4NKSzVyPUG1MlE6PzlizszN NVTlPWQ2W0GQR1XS
RPMI-8866 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlnETWM2OD1zNz60OFU1KM7:TR?= NVPL[Y9qW0GQR1XS
NCI-H510A NUL3OpBJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVjJR|UxRTF7LkO5O|Mh|ryP M{DRRXNCVkeHUh?=
NB13 M37pc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF3mfppKSzVyPUG5MlQ5PzdizszN M1X4Z3NCVkeHUh?=
HAL-01 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYfQeXJlUUN3ME2xPU44PTR|IN88US=> NFHzUHdUSU6JRWK=
NCI-H720 NXraNIdPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVrJR|UxRTJyLkK3N|Mh|ryP NHG4[YJUSU6JRWK=
REH NVm0eWFzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXfQ[4ZJUUN3ME2yNE43OzV5IN88US=> Ml75V2FPT0WU
KNS-81-FD Mkj1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;ifZZEUUN3ME2yN{4yPDZizszN MoTnV2FPT0WU
HC-1 MnnDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV62U203UUN3ME2yOE42PTVzIN88US=> MWfTRW5ITVJ?
NCI-H2141 MorGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFrL[IVKSzVyPUK0Mlc4PTRizszN MVHTRW5ITVJ?
MOLT-4 NFTmS|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVewd5pHUUN3ME2yOk43PzV|IN88US=> NVjzS3drW0GQR1XS
OMC-1 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWrJR|UxRTJ5LkG0NlIh|ryP MVzTRW5ITVJ?
LC-1F NIDYPJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH3wclBKSzVyPUK3MlMzPDVizszN M4rIenNCVkeHUh?=
NCI-H1304 NGjxToRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3nWRWlEPTB;MkiuNVYzQCEQvF2= M1\wS3NCVkeHUh?=
BC-1 NHTYUGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4PLOmlEPTB;MkiuOlUyKM7:TR?= M1\qVnNCVkeHUh?=
NCI-H64 NVewNGJsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV;IPIVxUUN3ME2yPU43OjV|IN88US=> MkXQV2FPT0WU
MOLT-16 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnPXTWM2OD1{OT62NlkzKM7:TR?= NFy3SIpUSU6JRWK=
U-87-MG MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MknGTWM2OD1|MD63OlYh|ryP Ml7YV2FPT0WU
GAK M3rm[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE\VbmhKSzVyPUOxMlI3QDZizszN MnfZV2FPT0WU
ES8 MofsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTN{LkGyOVIh|ryP NXvSSFZOW0GQR1XS
HCC1599 MkTZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGO5cohKSzVyPUOyMlM{OjVizszN MlnrV2FPT0WU
EB-3 M2SzcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUjLSmFqUUN3ME2zOE4{OTF5IN88US=> MoWwV2FPT0WU
HCC1187 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1PEOmlEPTB;M{WuPFA2OiEQvF2= MYnTRW5ITVJ?
SK-PN-DW MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn:1TWM2OD1|Nj6xPVQ{KM7:TR?= NV\0NXU6W0GQR1XS
JVM-3 MnTkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHfHfo5KSzVyPUO3MlI{OzhizszN NIHQ[oxUSU6JRWK=
HCC2157 Mnq3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3S3OWlEPTB;M{euPVk1PiEQvF2= NF\vW5FUSU6JRWK=
A4-Fuk MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGfrTYVKSzVyPUO4MlExODlizszN NFPzeIlUSU6JRWK=
COR-L279 NVnBU|ZoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mm[yTWM2OD12MD6yPFUyKM7:TR?= MXjTRW5ITVJ?
DEL Mk\JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHrRRZNKSzVyPUSxMlkxQDZizszN MV\TRW5ITVJ?
NCI-H1395 M1HVOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGrCZY9KSzVyPUSyMlAyPjNizszN NFLtZ4pUSU6JRWK=
MHH-NB-11 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlLCTWM2OD12Mz6wPFE5KM7:TR?= NWDPToNrW0GQR1XS
NCI-H2107 NHrYWpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVPJR|UxRTR|LkS4OFYh|ryP NVq3RW5xW0GQR1XS
NEC8 NF3J[2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV22e48{UUN3ME20OE4{OzZizszN NXn1NXNIW0GQR1XS
COLO-684 Mlu0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIWxblZKSzVyPUS2MlIzPThizszN NHLyUopUSU6JRWK=
LS-411N MknQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlPRTWM2OD12OD60O|Q5KM7:TR?= NUizZ5c6W0GQR1XS

... Click to View More Cell Line Experimental Data

In vivo Dasatinib reverses splenomegaly in LMP2A/MYC double transgenic mice. Dasatinib specifically prevents colony formation by LMP2A expressing bone marrow B cells and decreased spleen size in the TgE mice. Spleen mass is significantly decreased among Dasatinib treated Tg6/λ-MYC mice when compared to the control group. Dasatinib inhibits lymphadenopathy in LMP2A/MYC double transgenic mice. Dasatinib reverses splenomegaly in Rag1KO mice engrafted with tumor cells from LMP2A/MYC double transgenic mice. Dasatinib therapy inhibits Lyn phosphorylation in B lymphocyte tumors expressing LMP2A. [3]

Protocol

Kinase Assay:

[1]

+ Expand

Kinase autophosphorylation assays:

Kinase assays using wild-type and mutant glutathione S-transferase (GST)-Abl fusion proteins (c-Abl amino acids 220-498) are done. GST-Abl fusion proteins are released from glutathione-Sepharose beads before use; the concentration of ATP is 5 μM. Immediately before use in kinase autophosphorylation and in vitro peptide substrate phosphorylation assays, GST-Abl kinase domain fusion proteins are treated with LAR tyrosine phosphatase. After 1-hour incubation at 30 °C, LAR phosphatase is inactivated by addition of sodium vanadate (1 mM). Immunoblot analysis comparing untreated GST-Abl kinase to dephosphorylated GST-Abl kinase is routinely done using phosphotyrosine-specific antibody 4G10 to confirm complete (>95%) dephosphorylation of tyrosine residues and c-Abl antibody CST 2862 to confirm equal loading of GST-Abl kinase. The Dasatinib concentration range is extended to 1,000 nM for mutant T315I. These same inhibitor concentrations are used for the in vitro peptide substrate phosphorylation assays. The three inhibitors are tested over these same concentration ranges against GST-Src kinase and GST-Lyn kinase.
Cell Research:

[1]

+ Expand
  • Cell lines: Ba/F3 cell lines
  • Concentrations: ~32 nM
  • Incubation Time: 72 hours
  • Method:

    Ba/F3 cell lines are seeded in triplicate and incubated with escalating concentrations of Dasatinib for 72 hours. Proliferation is measured using a methanethiosulfonate-based viability assay. IC50 and IC90 values are reported as the mean of three independent experiments done in quadruplicate. The inhibitor concentration ranges are 0 nM to 32 nM (Dasatinib). The Dasatinib concentration range is extended to 200 nM for mutant T315I.


    (Only for Reference)
Animal Research:

[3]

+ Expand
  • Animal Models: EμLMP2A (TgE and Tg6 strains), MYC (λ-MYC), and LMP2A/λ-MYC double transgenic mice (Tg6/λ-MYC)
  • Formulation: DMSO
  • Dosages: 30 mg/kg
  • Administration: Administered via i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 98 mg/mL (200.81 mM)
Water <1 mg/mL
Ethanol <1 mg/mL
In vivo 4% DMSO+30% PEG 300+5% Tween 80+ddH2O 5mg/mL

* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 488.01
Formula

C22H26ClN7O2S

CAS No. 302962-49-8
Storage powder
in solvent
Synonyms BMS-354825

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01445509 Active, not recruiting Solid Tumors National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) October 27, 2008 Phase 1
NCT03041701 Not yet recruiting Rhabdomyosarcoma|Rhabdomyosarcoma- Alveolar|Rhabdomyosarcoma-Embryonal National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) January 24, 2017 Phase 1|Phase 2
NCT03023046 Not yet recruiting Adult Acute Lymphoblastic Leukemia|Adult Lymphoblastic Lymphoma|CD20 Positive|Philadelphia Chromosome Positive University of Washington|National Cancer Institute (NCI) February 2017 Phase 2
NCT03020030 Not yet recruiting Acute Lymphoblastic Leukemia, Pediatric Dana-Farber Cancer Institute|Baxalta US Inc. January 2017 Phase 3
NCT02744768 Not yet recruiting Acute Lymphoblastic Leukemia Gruppo Italiano Malattie EMatologiche dellAdulto December 2016 Phase 2
NCT02923986 Not yet recruiting Chronic Myelogenous Leukemia, Ph1-Positive Bio-Path Holdings, Inc. November 2016 Phase 1|Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Src Signaling Pathway Map

Src Inhibitors with Unique Features

Related Src Products

Tags: buy Dasatinib | Dasatinib supplier | purchase Dasatinib | Dasatinib cost | Dasatinib manufacturer | order Dasatinib | Dasatinib distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID